Sorting peripheral blood mononuclear cells from lassa fever virus survivors to discover and produce monoclonal antibodies for assessment in in vitro and in vivo assays
Ended Purchase Order Awarded Last action
- Contract number
- HT942524P0015
- Awardee
-
Eitr Biologics, Inc. UEI HX49LZLY32G5
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $729,721
Award facts
- Opportunity
-
- Lassa fever virus (LASV) cell sorting for monoclonal antibody discovery for usamriid - amendment 0001 - questions from offerors Solicitation · HT942523Q0059 · Posted Jun 22, 2023
- Contract value 56% obligated
-
- $729,720.96 Current, with exercised options
- $1,303,426.92 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- Total Small Business
- Competition
- Competed under SAP · 2 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92121, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $132,918 | |
| Supplemental Agreement for work within scope | -$273 | |
| Exercise an Option | $66,732 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $530,344 |
About this award
The Defense Health Agency awarded a $1.3 million firm fixed-price purchase order to Eitr Biologics, Inc., a San Diego-based biotechnology company specializing in antibody discovery and viral countermeasures. The contract, set aside for small business, focuses on sorting peripheral blood mononuclear cells from Lassa fever virus survivors to discover and produce monoclonal antibodies for subsequent assessment in in vitro and in vivo assays. This work supports the Defense Health Agency's medical countermeasures portfolio by leveraging survivor-derived immune cells to identify therapeutic antibody candidates against one of the most dangerous hemorrhagic fever viruses. The award, made on December 6, 2023, with completion targeted for December 10, 2026, represents continued federal investment in Eitr Biologics' core capabilities in cell sorting and antibody engineering.
This purchase order operates under or complements Eitr Biologics' existing $4.4 million indefinite delivery vehicle with the Defense Health Agency through August 2028, which focuses on developing novel nanotherapeutics for biological threats. The company has demonstrated sustained expertise across multiple Defense Health Agency projects involving advanced medical countermeasures against infectious diseases, including pneumonic plague, Venezuelan Equine Encephalitis Virus, and influenza. By isolating and characterizing antibodies from naturally immune Lassa fever survivors, this contract leverages passive immunotherapy approaches that could yield rapid medical countermeasures for a Select agent pathogen of significant biosecurity concern.
Quick answers
Who was awarded contract HT942524P0015?
HT942524P0015 was awarded to Eitr Biologics, Inc. by Defense Health Agency (Department of Defense) on December 6, 2023.
How much is contract HT942524P0015 worth?
The government has obligated $729,721 on HT942524P0015. Its potential value, with all options, is $1,303,427.
Was contract HT942524P0015 competed?
The extent of competition for HT942524P0015 was competed under sap. The government received 2 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award